Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
20
HERB Quote, Financials, Valuation and Earnings
Last price:
$0.0500
Seasonality move
:
0.46%
Day range:
$0.0200 - $0.0200
52-week range:
$0.0150 - $0.1450
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
0.01x
Volume:
--
Avg. volume:
20.4K
1-year change:
-69.23%
Market cap:
$3.1M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Yasheng Group has -- downside to fair value with a price target of -- per share.
HERB vs. S&P 500
-
Over the past 5 trading days, Yasheng Group has underperformed the S&P 500 by -35.87% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Yasheng Group does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Yasheng Group revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Yasheng Group reported revenues of --.
Earnings Growth
-
Yasheng Group earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Yasheng Group reported earnings per share of --.
Enterprise value:
47.4M
EV / Invested capital:
--
Price / LTM sales:
0.00x
EV / EBIT:
0.42x
EV / Revenue:
0.05x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.15x
Price / Operating cash flow:
0.01x
Enterprise value / EBITDA:
0.37x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2013-12-31 | 2014-12-31 | 2015-12-31 | 2014-12-31 | 2015-12-31 | |
| Income Statement | ||||||
| Revenue | $1B | $1B | $938.9M | $303.6M | $229.3M | |
| Gross Profit | $143.5M | $142.9M | $119.2M | $50.6M | $25M | |
| Operating Income | $136.7M | $136.9M | $113.1M | $49.1M | $23.3M | |
| EBITDA | $150.5M | $151.6M | $129M | $51.2M | $27.2M | |
| Diluted EPS | $0.86 | $0.88 | $0.71 | $0.30 | $0.14 | |
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2014-12-31 | 2015-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $235.9M | $334.1M | $437.8M | $469.8M | $118.2M | |
| Total Assets | $2.1B | $2.2B | $2.4B | $2.5B | $258.3M | |
| Current Liabilities | $62.2M | $41.1M | $44M | $37.2M | $99.4K | |
| Total Liabilities | $98.4M | $69.2M | $68.5M | $58.2M | $45.8M | |
| Total Equity | $2B | $2.1B | $2.3B | $2.4B | $212.6M | |
| Total Debt | $21.7M | $14.5M | $24.6M | $21.1M | $45.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2013-12-31 | 2014-12-31 | 2015-12-31 | 2014-12-31 | 2015-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $51.1M | $68.1M | $321M | $24.8M | $278.3M | |
| Cash From Investing | -$43.8M | -$61.9M | -$324.3M | -$25M | -$285.9M | |
| Cash From Financing | -$8.4M | -$5.9M | $2.1M | -$1.8M | $4.8M | |
| Free Cash Flow | $51.1M | $68.1M | $321M | $24.8M | $278.3M | |
HERB
Sector
Market Cap
$3.1M
$246.8M
Price % of 52-Week High
13.79%
75.43%
Dividend Yield
0%
0%
Shareholder Yield
--
2.89%
1-Year Price Total Return
-69.23%
-10.65%
Beta (5-Year)
0.489
0.377
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0283
200-day SMA
Sell
Level
$0.0570
Bollinger Bands (100)
Sell
Level
0.0312 - 0.0512
Chaikin Money Flow
Sell
Level
-11.9K
20-day SMA
Sell
Level
$0.0335
Relative Strength Index (RSI14)
Sell
Level
31.9828
ADX Line
Sell
Level
13.7755
Williams %R
Buy
Level
-80.7692
50-day SMA
Sell
Level
$0.0340
MACD (12, 26)
Buy
Level
0.0070
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-43.3K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
HUMANOID INC, formerly Yasheng Group, is a Colorado corporation U.S. company, that conducts business operations in the U.S., China, Philippines through four segments: Mining, Agriculture and Biotechnology, and Blockchain+ IOT. The company's agricultural products include herbal medicine, herbal organic food, ginkgo, songaricum, betel nut, coconut, coffee, wolfberry, hemp, etc. It also designs, develops, and markets new technologies related to agriculture and genetic biology.
Stock Forecast FAQ
In the current month, HERB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HERB average analyst price target in the past 3 months is --.
-
Where Will Yasheng Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that Yasheng Group share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Yasheng Group?
Analysts are divided on their view about Yasheng Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Yasheng Group is a Sell and believe this share price will rise from its current level to --.
-
What Is Yasheng Group's Price Target?
The price target for Yasheng Group over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HERB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Yasheng Group is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of HERB?
You can purchase shares of Yasheng Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Yasheng Group shares.
-
What Is The Yasheng Group Share Price Today?
Yasheng Group was last trading at $0.0500 per share. This represents the most recent stock quote for Yasheng Group. Yesterday, Yasheng Group closed at $0.0200 per share.
-
How To Buy Yasheng Group Stock Online?
In order to purchase Yasheng Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
80
SOC alert for Jul 18
Sable Offshore [SOC] is up 11.86% over the past day.
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 5.56% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 0.31% over the past day.
